Last 12 months
Inside the activity.
0 purchase rows · 19 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 2 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 1 |
| Mar 2026 | 0 | 1 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 3 |
| Jun 2026 | 0 | 2 |
| Jul 2026 | 0 | 1 |
| Aug 2026 | 0 | 4 |
| Sep 2026 | 0 | 5 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 26, 2020 Filed Jun 30, 2020 22:45 UTC |
Bancel StephaneDirector · Chief Executive Officer
|
SaleCommon Stock | 932 | $61.69 | $57,495.08 |
DisclosureSEC source: 0001104659-20-079182 · a4.xml · nonDerivative · entry 3 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 530,224 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $61.38 to $62.21. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · ownership.nature: These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. Read SEC document |
| June 26, 2020 Filed Jun 30, 2020 22:45 UTC |
Bancel StephaneDirector · Chief Executive Officer
|
SaleCommon Stock | 6,914 | $60.85 | $420,716.90 |
DisclosureSEC source: 0001104659-20-079182 · a4.xml · nonDerivative · entry 2 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 531,156 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $60.36 to $61.34. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · ownership.nature: These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. Read SEC document |
| June 26, 2020 Filed Jun 30, 2020 22:45 UTC |
Bancel StephaneDirector · Chief Executive Officer
|
SaleCommon Stock | 3,200 | $59.90 | $191,680.00 |
DisclosureSEC source: 0001104659-20-079182 · a4.xml · nonDerivative · entry 1 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 538,070 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $59.29 to $60.28. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · ownership.nature: These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. Read SEC document |
| June 25, 2020 Filed Jun 30, 2020 22:41 UTC |
Bancel StephaneDirector · Chief Executive Officer
|
SaleCommon Stock | 10,000 | $67.00 | $670,000.00 |
DisclosureSEC source: 0001104659-20-079181 · a4.xml · nonDerivative · entry 1 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 7,874,880 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 18, 2018, as amended on May 21, 2020. F2 · ownership.nature: These shares are owned directly by OCHA LLC ("OCHA"). The reporting person is the majority equity unit holder and the sole managing member of OCHA. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. Read SEC document |
| June 24, 2020 Filed Jun 25, 2020 22:04 UTC |
Hoge StephenPresident
|
SaleCommon Stock | 200 | $65.84 | $13,168.00 |
DisclosureSEC source: 0001127602-20-020360 · form4.xml · nonDerivative · entry 6 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,976,540 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018. F6 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $65.78 to $65.90. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| June 24, 2020 Filed Jun 25, 2020 22:04 UTC |
Hoge StephenPresident
|
SaleCommon Stock | 2,595 | $65.11 | $168,960.45 |
DisclosureSEC source: 0001127602-20-020360 · form4.xml · nonDerivative · entry 5 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,976,740 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $64.72 to $65.54. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| June 24, 2020 Filed Jun 25, 2020 22:04 UTC |
Hoge StephenPresident
|
SaleCommon Stock | 2,205 | $64.33 | $141,847.65 |
DisclosureSEC source: 0001127602-20-020360 · form4.xml · nonDerivative · entry 4 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,979,335 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $63.70 to $64.70. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| June 24, 2020 Filed Jun 25, 2020 22:00 UTC |
Bancel StephaneDirector · Chief Executive Officer
|
GiftCommon Stock | 1,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-020358 · form4.xml · nonDerivative · entry 2 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,724,858 F2 · kind: The reported disposition was effected pursuant to a Rule 10b5-1 trading plan adopted on September 16, 2019, as amended on May 21, 2020. F3 · price: The reported disposition represents a bona fide charitable gift made by the reporting person. Read SEC document |
| June 24, 2020 Filed Jun 25, 2020 22:00 UTC |
Bancel StephaneDirector · Chief Executive Officer
|
SaleCommon Stock | 9,000 | $63.25 | $569,250.00 |
DisclosureSEC source: 0001127602-20-020358 · form4.xml · nonDerivative · entry 1 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,725,858 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018, as amended on May 21, 2020. Read SEC document |
| June 23, 2020 Filed Jun 25, 2020 22:04 UTC |
Hoge StephenPresident
|
SaleCommon Stock | 100 | $64.95 | $6,495.00 |
DisclosureSEC source: 0001127602-20-020360 · form4.xml · nonDerivative · entry 3 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,981,540 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018. Read SEC document |
| June 23, 2020 Filed Jun 25, 2020 22:04 UTC |
Hoge StephenPresident
|
SaleCommon Stock | 1,891 | $64.19 | $121,383.29 |
DisclosureSEC source: 0001127602-20-020360 · form4.xml · nonDerivative · entry 2 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,981,640 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $63.87 to $64.81. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| June 23, 2020 Filed Jun 25, 2020 22:04 UTC |
Hoge StephenPresident
|
SaleCommon Stock | 3,009 | $63.34 | $190,590.06 |
DisclosureSEC source: 0001127602-20-020360 · form4.xml · nonDerivative · entry 1 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,983,531 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $62.86 to $63.81. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| June 23, 2020 Filed Jun 25, 2020 22:08 UTC |
Zaks Tal ZviChief Medical Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 15,631 | $0.00 Strike: $19.15 | $0.00 |
DisclosureSEC source: 0001127602-20-020362 · form4.xml · derivative · entry 7 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 324,294 Underlying: Common Stock · 15,631 shares Expires 2026-08-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. F5 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| June 23, 2020 Filed Jun 25, 2020 22:08 UTC |
Zaks Tal ZviChief Medical Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 24,121 | $0.00 Strike: $19.15 | $0.00 |
DisclosureSEC source: 0001127602-20-020362 · form4.xml · derivative · entry 6 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 339,925 Underlying: Common Stock · 24,121 shares Expires 2026-08-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. F5 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| June 23, 2020 Filed Jun 25, 2020 22:08 UTC |
Zaks Tal ZviChief Medical Officer
|
SaleCommon Stock | 1,500 | $64.94 | $97,410.00 |
DisclosureSEC source: 0001127602-20-020362 · form4.xml · nonDerivative · entry 5 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $64.89 to $65.01. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| June 23, 2020 Filed Jun 25, 2020 22:08 UTC |
Zaks Tal ZviChief Medical Officer
|
SaleCommon Stock | 14,279 | $64.16 | $916,140.64 |
DisclosureSEC source: 0001127602-20-020362 · form4.xml · nonDerivative · entry 4 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $63.86 to $64.85. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| June 23, 2020 Filed Jun 25, 2020 22:08 UTC |
Zaks Tal ZviChief Medical Officer
|
SaleCommon Stock | 23,973 | $63.37 | $1,519,169.01 |
DisclosureSEC source: 0001127602-20-020362 · form4.xml · nonDerivative · entry 3 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,779 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $62.85 to $63.85. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| June 23, 2020 Filed Jun 25, 2020 22:08 UTC |
Zaks Tal ZviChief Medical Officer
|
Exercise / conversionCommon Stock | 15,631 | $19.15 | $299,333.65 |
DisclosureSEC source: 0001127602-20-020362 · form4.xml · nonDerivative · entry 2 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,752 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. Read SEC document |
| June 23, 2020 Filed Jun 25, 2020 22:08 UTC |
Zaks Tal ZviChief Medical Officer
|
Exercise / conversionCommon Stock | 24,121 | $19.15 | $461,917.15 |
DisclosureSEC source: 0001127602-20-020362 · form4.xml · nonDerivative · entry 1 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,121 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. Read SEC document |
| June 22, 2020 Filed Jun 24, 2020 20:51 UTC |
Bancel StephaneDirector · Chief Executive Officer
|
SaleCommon Stock | 4,521 | $65.92 | $298,024.32 |
DisclosureSEC source: 0001127602-20-020320 · form4.xml · nonDerivative · entry 1 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 9,185,883 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on 12/18/2018, as amended on 9/16/2019. F2 · ownership.nature: These shares are owned directly by Boston Biotech Ventures, LLC ("Boston Biotech"). The reporting person is the majority equity unit holder and the sole managing member of Boston Biotech. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. Read SEC document |
| June 19, 2020 Filed Jun 22, 2020 22:59 UTC |
Bancel StephaneDirector · Chief Executive Officer
|
SaleCommon Stock | 500 | $65.52 | $32,760.00 |
DisclosureSEC source: 0001127602-20-020206 · form4.xml · nonDerivative · entry 2 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 541,270 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on 12/28/2018. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $65.08 to $66.00. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · ownership.nature: These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. Read SEC document |
| June 19, 2020 Filed Jun 22, 2020 22:59 UTC |
Bancel StephaneDirector · Chief Executive Officer
|
SaleCommon Stock | 10,546 | $64.57 | $680,955.22 |
DisclosureSEC source: 0001127602-20-020206 · form4.xml · nonDerivative · entry 1 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 541,770 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on 12/28/2018. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $64.04 to $65.02. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · ownership.nature: These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. Read SEC document |
| June 18, 2020 Filed Jun 19, 2020 23:24 UTC |
HENDERSON LORI M.General Counsel and Secretary
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 64,000 | $0.00 Strike: $14.85 | $0.00 |
DisclosureSEC source: 0001127602-20-020118 · form4.xml · derivative · entry 3 HENDERSON LORI M. · CIK 0001221127 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 399,522 Underlying: Common Stock · 64,000 shares Expires 2028-06-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 6, 2020. F3 · derivative.exercise_date: 25% of this option will vest and become exercisable on April 9, 2019 with the remainder vesting in 12 equal quarterly installments thereafter. Read SEC document |
| June 18, 2020 Filed Jun 19, 2020 23:24 UTC |
HENDERSON LORI M.General Counsel and Secretary
|
SaleCommon Stock | 64,000 | $63.03 | $4,033,920.00 |
DisclosureSEC source: 0001127602-20-020118 · form4.xml · nonDerivative · entry 2 HENDERSON LORI M. · CIK 0001221127 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 681 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 6, 2020. Read SEC document |
| June 18, 2020 Filed Jun 19, 2020 23:24 UTC |
HENDERSON LORI M.General Counsel and Secretary
|
Exercise / conversionCommon Stock | 64,000 | $14.85 | $950,400.00 |
DisclosureSEC source: 0001127602-20-020118 · form4.xml · nonDerivative · entry 1 HENDERSON LORI M. · CIK 0001221127 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,681 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 6, 2020. F2 · balance_after: Includes 681 shares acquired under the Moderna, Inc. 2018 Employee Stock Purchase Plan on May 29, 2020. Read SEC document |
| June 16, 2020 Filed Jun 18, 2020 22:42 UTC |
Zaks Tal ZviChief Medical Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 15,631 | $0.00 Strike: $19.15 | $0.00 |
DisclosureSEC source: 0001127602-20-020083 · form4.xml · derivative · entry 8 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 364,046 Underlying: Common Stock · 15,631 shares Expires 2026-08-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. F6 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| June 16, 2020 Filed Jun 18, 2020 22:42 UTC |
Zaks Tal ZviChief Medical Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 24,121 | $0.00 Strike: $19.15 | $0.00 |
DisclosureSEC source: 0001127602-20-020083 · form4.xml · derivative · entry 7 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 379,677 Underlying: Common Stock · 24,121 shares Expires 2026-08-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. F6 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| June 16, 2020 Filed Jun 18, 2020 22:42 UTC |
Zaks Tal ZviChief Medical Officer
|
SaleCommon Stock | 300 | $66.58 | $19,974.00 |
DisclosureSEC source: 0001127602-20-020083 · form4.xml · nonDerivative · entry 6 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $66.57 to $66.58. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| June 16, 2020 Filed Jun 18, 2020 22:42 UTC |
Zaks Tal ZviChief Medical Officer
|
SaleCommon Stock | 1,000 | $65.69 | $65,690.00 |
DisclosureSEC source: 0001127602-20-020083 · form4.xml · nonDerivative · entry 5 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $65.49 to $65.96. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| June 16, 2020 Filed Jun 18, 2020 22:42 UTC |
Zaks Tal ZviChief Medical Officer
|
SaleCommon Stock | 16,320 | $64.08 | $1,045,785.60 |
DisclosureSEC source: 0001127602-20-020083 · form4.xml · nonDerivative · entry 4 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,300 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $63.83 to $64.75. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| June 16, 2020 Filed Jun 18, 2020 22:42 UTC |
Zaks Tal ZviChief Medical Officer
|
SaleCommon Stock | 22,132 | $63.40 | $1,403,168.80 |
DisclosureSEC source: 0001127602-20-020083 · form4.xml · nonDerivative · entry 3 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,620 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $62.82 to $63.82. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| June 16, 2020 Filed Jun 18, 2020 22:42 UTC |
Zaks Tal ZviChief Medical Officer
|
Exercise / conversionCommon Stock | 15,631 | $19.15 | $299,333.65 |
DisclosureSEC source: 0001127602-20-020083 · form4.xml · nonDerivative · entry 2 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,752 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. Read SEC document |
| June 16, 2020 Filed Jun 18, 2020 22:42 UTC |
Zaks Tal ZviChief Medical Officer
|
Exercise / conversionCommon Stock | 24,121 | $19.15 | $461,917.15 |
DisclosureSEC source: 0001127602-20-020083 · form4.xml · nonDerivative · entry 1 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,121 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. Read SEC document |
| June 15, 2020 Filed Jun 16, 2020 20:23 UTC |
Hoge StephenPresident
|
SaleCommon Stock | 910 | $66.42 | $60,442.20 |
DisclosureSEC source: 0001127602-20-019728 · form4.xml · nonDerivative · entry 6 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,986,540 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018. F7 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $65.97 to $66.82. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| June 15, 2020 Filed Jun 16, 2020 20:23 UTC |
Hoge StephenPresident
|
SaleCommon Stock | 1,500 | $65.36 | $98,040.00 |
DisclosureSEC source: 0001127602-20-019728 · form4.xml · nonDerivative · entry 5 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,987,450 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018. F6 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $64.92 to $65.91. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| June 15, 2020 Filed Jun 16, 2020 20:23 UTC |
Hoge StephenPresident
|
SaleCommon Stock | 2,590 | $64.27 | $166,459.30 |
DisclosureSEC source: 0001127602-20-019728 · form4.xml · nonDerivative · entry 4 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,988,950 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $63.79 to $64.73. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| June 12, 2020 Filed Jun 16, 2020 20:23 UTC |
Hoge StephenPresident
|
SaleCommon Stock | 500 | $62.90 | $31,450.00 |
DisclosureSEC source: 0001127602-20-019728 · form4.xml · nonDerivative · entry 3 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,991,540 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $62.49 to $63.17. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| June 12, 2020 Filed Jun 16, 2020 20:23 UTC |
Hoge StephenPresident
|
SaleCommon Stock | 2,407 | $61.88 | $148,945.16 |
DisclosureSEC source: 0001127602-20-019728 · form4.xml · nonDerivative · entry 2 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,992,040 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $61.47 to $62.43. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| June 12, 2020 Filed Jun 16, 2020 20:23 UTC |
Hoge StephenPresident
|
SaleCommon Stock | 2,093 | $61.10 | $127,882.30 |
DisclosureSEC source: 0001127602-20-019728 · form4.xml · nonDerivative · entry 1 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,994,447 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $60.46 to $61.45. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| June 12, 2020 Filed Jun 16, 2020 20:20 UTC |
Bancel StephaneDirector · Chief Executive Officer
|
SaleCommon Stock | 700 | $63.03 | $44,121.00 |
DisclosureSEC source: 0001127602-20-019726 · form4.xml · nonDerivative · entry 3 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 552,316 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on 12/28/2018. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $62.93 to $63.17. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · ownership.nature: These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. Read SEC document |
| June 12, 2020 Filed Jun 16, 2020 20:20 UTC |
Bancel StephaneDirector · Chief Executive Officer
|
SaleCommon Stock | 5,346 | $61.93 | $331,077.78 |
DisclosureSEC source: 0001127602-20-019726 · form4.xml · nonDerivative · entry 2 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 553,016 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on 12/28/2018. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $61.53 to $62.53. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · ownership.nature: These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. Read SEC document |
| June 12, 2020 Filed Jun 16, 2020 20:20 UTC |
Bancel StephaneDirector · Chief Executive Officer
|
SaleCommon Stock | 5,000 | $61.13 | $305,650.00 |
DisclosureSEC source: 0001127602-20-019726 · form4.xml · nonDerivative · entry 1 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 558,362 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on 12/28/2018. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $60.52 to $61.52. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · ownership.nature: These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. Read SEC document |
| June 10, 2020 Filed Jun 11, 2020 20:12 UTC |
Bancel StephaneDirector · Chief Executive Officer
|
SaleCommon Stock | 3,435 | $58.80 | $201,978.00 |
DisclosureSEC source: 0001127602-20-019421 · form4.xml · nonDerivative · entry 1 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 9,190,404 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on 12/18/2018, as amended on 9/16/2019. F2 · ownership.nature: These shares are owned directly by Boston Biotech Ventures, LLC ("Boston Biotech"). The reporting person is the majority equity unit holder and the sole managing member of Boston Biotech. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. Read SEC document |
| June 09, 2020 Filed Jun 10, 2020 20:28 UTC |
Zaks Tal ZviChief Medical Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 15,631 | $0.00 Strike: $19.15 | $0.00 |
DisclosureSEC source: 0001127602-20-019353 · form4.xml · derivative · entry 6 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 403,798 Underlying: Common Stock · 15,631 shares Expires 2026-08-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. F4 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| June 09, 2020 Filed Jun 10, 2020 20:28 UTC |
Zaks Tal ZviChief Medical Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 24,121 | $0.00 Strike: $19.15 | $0.00 |
DisclosureSEC source: 0001127602-20-019353 · form4.xml · derivative · entry 5 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 419,429 Underlying: Common Stock · 24,121 shares Expires 2026-08-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. F4 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| June 09, 2020 Filed Jun 10, 2020 20:28 UTC |
Zaks Tal ZviChief Medical Officer
|
SaleCommon Stock | 9,080 | $58.95 | $535,266.00 |
DisclosureSEC source: 0001127602-20-019353 · form4.xml · nonDerivative · entry 4 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $58.81 to $59.15. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| June 09, 2020 Filed Jun 10, 2020 20:28 UTC |
Zaks Tal ZviChief Medical Officer
|
SaleCommon Stock | 30,672 | $58.33 | $1,789,097.76 |
DisclosureSEC source: 0001127602-20-019353 · form4.xml · nonDerivative · entry 3 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,080 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $57.80 to $58.80. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| June 09, 2020 Filed Jun 10, 2020 20:28 UTC |
Zaks Tal ZviChief Medical Officer
|
Exercise / conversionCommon Stock | 15,631 | $19.15 | $299,333.65 |
DisclosureSEC source: 0001127602-20-019353 · form4.xml · nonDerivative · entry 2 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,752 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. Read SEC document |
| June 09, 2020 Filed Jun 10, 2020 20:28 UTC |
Zaks Tal ZviChief Medical Officer
|
Exercise / conversionCommon Stock | 24,121 | $19.15 | $461,917.15 |
DisclosureSEC source: 0001127602-20-019353 · form4.xml · nonDerivative · entry 1 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,121 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. Read SEC document |
| June 05, 2020 Filed Jun 9, 2020 23:41 UTC |
Bancel StephaneDirector · Chief Executive Officer
|
SaleCommon Stock | 400 | $58.90 | $23,560.00 |
DisclosureSEC source: 0001127602-20-019271 · form4.xml · nonDerivative · entry 3 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 563,362 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on 12/28/2018. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $58.84 to $58.95. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · ownership.nature: These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.